Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Breast Cancer Resource Center

William J. Gradishar, MD
Videos
HR-Positive and HER2-Negative Breast Cancer Treatment Updates
06/04/2024
William J. Gradishar, MD
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
Reshma Mahtani, DO, Terry Mamounas, MD, Jane Meisel, MD
Videos
Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer
02/15/2024
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of...
02/15/2024
Oncology
From Oncology
News
Capivasertib Plus Palbociclib and Fulvestrant Demonstrated Safety, Tolerability Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
01/16/2024

Stephanie Holland

Stephanie Holland
Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.
Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.
Updated phase 1b results from...
01/16/2024
Oncology
From Oncology
Conference Coverage
Impact of Implementing Universal Germline Genetic Testing for Breast Cancer in Rural Communities
12/06/2023

Edited by Brandon Twyford

Edited by Brandon Twyford
New research underscores the high implementation rate and significant impact of universal germline genetic testing (GGT) for breast cancer (BC) in rural medical practices on shared treatment decision-making.
New research underscores the high implementation rate and significant impact of universal germline genetic testing (GGT) for breast cancer (BC) in rural medical practices on shared treatment decision-making.
New research underscores the...
12/06/2023
Journal of Clinical Pathways
Conference Coverage
Adverse Event-Related Health Care Utilization and Cost Among Patients with HR+/HER2- Metastatic Breast Cancer
12/06/2023

Edited by Brandon Twyford

Edited by Brandon Twyford
Research presented at SABCS 2023 examines the economic impact of treating HR+/HER2- metastatic breast cancer, revealing that costs related to adverse events in patients undergoing late-line chemotherapy treatments are significant and...
Research presented at SABCS 2023 examines the economic impact of treating HR+/HER2- metastatic breast cancer, revealing that costs related to adverse events in patients undergoing late-line chemotherapy treatments are significant and...
Research presented at SABCS 2023...
12/06/2023
Journal of Clinical Pathways
News
Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis
12/06/2023

Edited by: Grace Taylor

Edited by: Grace Taylor
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and...
12/06/2023
Journal of Clinical Pathways
Conference Coverage
Study Reveals Insights into Cost-Effectiveness of Multigene Assays in Early-Stage Breast Cancer Treatment
12/06/2023

Edited by Brandon Twyford

Edited by Brandon Twyford
A recent study presented at the 2023 ASH Annual Meeting & Exposition compared the cost-effectiveness of four multigene assays used in early-stage breast cancer treatment, and revealed which was the most beneficial for cost savings and...
A recent study presented at the 2023 ASH Annual Meeting & Exposition compared the cost-effectiveness of four multigene assays used in early-stage breast cancer treatment, and revealed which was the most beneficial for cost savings and...
A recent study presented at the...
12/06/2023
Journal of Clinical Pathways
John A. Ingoglia, PharmD
Videos
Utilizing Clinical Pathways Tools at Cone Health
10/31/2023

Featuring John A. Ingoglia, PharmD, BCOP, CPP

Featuring John A. Ingoglia, PharmD, B...
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP,...
10/31/2023
Journal of Clinical Pathways

Expert Insights

William J. Gradishar, MD
Videos
HR-Positive and HER2-Negative Breast Cancer Treatment Updates
06/04/2024
William J. Gradishar, MD
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
Reshma Mahtani, DO, Terry Mamounas, MD, Jane Meisel, MD
Videos
Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer
02/15/2024
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of...
02/15/2024
Oncology
John A. Ingoglia, PharmD
Videos
Utilizing Clinical Pathways Tools at Cone Health
10/31/2023

Featuring John A. Ingoglia, PharmD, BCOP, CPP

Featuring John A. Ingoglia, PharmD, B...
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP,...
10/31/2023
Journal of Clinical Pathways
Dr Danielle Gentile.
Videos
Comparison of Diversity Across Real-World Evidence, Randomized Clinical Trial, and SEER Data in Patients With Metastatic Breast Cancer
07/12/2023

Featuring Danielle Gentile, PhD

Featuring Danielle Gentile, PhD ...
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior...
07/12/2023
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways
Sara Tolaney, MD, MPH
Videos
Factors Associated With a Greater Risk of Treatment Discontinuation in High-Risk Early Breast Cancer
08/03/2022
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses...
08/03/2022
Journal of Clinical Pathways
Shlomit Amar-Farkash, PhD, MSc
Videos
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc,...
07/14/2022
Journal of Clinical Pathways
Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network
Videos
Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer
07/06/2022
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA,...
07/06/2022
Journal of Clinical Pathways
Ethan Sokol, PhD
Videos
Real-World Outcomes of HR-Positive HER2-Negative Metastatic Breast Cancer Treated With ICIs
10/21/2021
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses...
10/21/2021
Journal of Clinical Pathways
Weija Wang
Videos
Real-World Outcomes of Febrile Neutropenia Among Patients With Breast Cancer or Non-Hodgkin Lymphoma
05/27/2021
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses...
05/27/2021
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
BDHC thumbnail
Breaking Down Health Care
What Does Quality Mean in Health Care?
07/01/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, examine how to measure quality in health care and the current challenges with the existing methods.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, examine how to measure quality in health care and the current challenges with the existing methods.
In this Breaking Down Health...
07/01/2024
Cancer Care Business Exchange
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Tony Mok, MD
Conference Coverage
Adagrasib Improved Survival and Response Among Patients With KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
06/17/2024
Tony Mok, MD
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the...
06/17/2024
Oncology

Newsfeed

News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
Capivasertib Plus Palbociclib and Fulvestrant Demonstrated Safety, Tolerability Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
01/16/2024

Stephanie Holland

Stephanie Holland
Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.
Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.
Updated phase 1b results from...
01/16/2024
Oncology
News
Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis
12/06/2023

Edited by: Grace Taylor

Edited by: Grace Taylor
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and...
12/06/2023
Journal of Clinical Pathways
News
Study Explores the Cost-Effectiveness of Ultra-Hypofractionated Whole Breast Radiation Therapy vs Endocrine Therapy Alone vs Combination Therapy
02/14/2023

Yvette C Terrie

Yvette C Terrie
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022

Ellen Kurek

Ellen Kurek
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
News
Analyzing Experiences in Non-Medical Switching to Trastuzumab Biosimilars Among Oncologists and Patients With Breast Cancer
06/12/2022

Ellen Kurek

Ellen Kurek
Study findings suggest that there is a need for tailored patient and oncologist information and education on trastuzumab biosimilars, as well as improved health care communication regarding switching.
Study findings suggest that there is a need for tailored patient and oncologist information and education on trastuzumab biosimilars, as well as improved health care communication regarding switching.
Study findings suggest that...
06/12/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022

Ellen Kurek

Ellen Kurek
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Breast Conservation Yields Equal QOL Outcomes to Mastectomy and Reconstruction Among Patients With Breast Cancer
05/17/2022

Ellen Kurek

Ellen Kurek
A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.
A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.
A comparative effectiveness...
05/17/2022
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Trastuzumab Biosimilar for HER2-Positive Breast Cancer
03/17/2022
True or False: Trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
True or False: Trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
True or False: Trastuzumab...
03/17/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Treatments for Low-Risk Ductal Carcinoma in Situ
09/17/2021
True or False: No adjuvant therapy is the most cost-effective approach for postmenopausal women who receive partial mastectomy for low-risk ductal carcinoma in situ.
True or False: No adjuvant therapy is the most cost-effective approach for postmenopausal women who receive partial mastectomy for low-risk ductal carcinoma in situ.
True or False: No adjuvant...
09/17/2021
Journal of Clinical Pathways
Quiz
Quiz: Impact of Risk Factors on Incidence of Febrile Neutropenia in Patients With Breast Cancer
08/16/2021
True or False: The choice of febrile neutropenia (FN) definition significantly changes the impact of risk factors on FN outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim prophylaxis.
True or False: The choice of febrile neutropenia (FN) definition significantly changes the impact of risk factors on FN outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim prophylaxis.
True or False: The choice of...
08/16/2021
Journal of Clinical Pathways
Quiz
Quiz: Progression-Free Survival Among Patients With Breast Cancer and PIK3CA Mutations
07/12/2021
True or False: Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world progression-free survival compared with those who receive fulvestrant alone.
True or False: Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world progression-free survival compared with those who receive fulvestrant alone.
True or False: Patients with...
07/12/2021
Journal of Clinical Pathways
Quiz
Quiz: Adjuvant Hormonal Therapy Adherence Rates Among Patients With Breast Cancer
05/03/2021
05/03/2021
Journal of Clinical Pathways
Quiz
Quiz: How Can We Optimize Genetic Testing for Breast and Ovarian Cancer?
03/17/2021
03/17/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer
03/05/2021
03/05/2021
Journal of Clinical Pathways
Quiz
Quiz: Does Circulating Tumor Cell Count Help Determine Best Therapy Approach for Metastatic Breast Cancer?
01/28/2021
01/28/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Genomic Screening for Breast and Ovarian Cancer
12/30/2020
12/30/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

William J. Gradishar, MD
Videos
HR-Positive and HER2-Negative Breast Cancer Treatment Updates
06/04/2024
William J. Gradishar, MD
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
Reshma Mahtani, DO, Terry Mamounas, MD, Jane Meisel, MD
Videos
Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer
02/15/2024
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of...
02/15/2024
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement